ATNF180 Life Sciences Corp.

Nasdaq 180lifesciences.com


$ 1.93 $ 0.00 (0 %)    

Wednesday, 21-Aug-2024 14:05:14 EDT
QQQ $ 482.10 $ 0.98 (0.2 %)
DIA $ 408.92 $ -0.32 (-0.08 %)
SPY $ 560.38 $ 0.45 (0.08 %)
TLT $ 99.03 $ 0.35 (0.35 %)
GLD $ 232.47 $ 0.81 (0.35 %)
$ 1.86
$ 1.93
$ 1.86 x 100
$ 1.94 x 100
$ 1.93 - $ 1.93
$ 1.31 - $ 15.72
11,748
na
1.71M
$ 0.72
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-23-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-15-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-31-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 07-16-2021 03-31-2021 10-Q
15 07-09-2021 12-31-2020 10-K
16 11-24-2020 09-30-2020 10-Q
17 08-20-2020 06-30-2020 10-Q
18 05-22-2020 03-31-2020 10-Q
19 04-07-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-09-2019 06-30-2019 10-Q
22 05-13-2019 03-31-2019 10-Q
23 04-01-2019 12-31-2018 10-K
24 11-09-2018 09-30-2018 10-Q
25 08-14-2018 06-30-2018 10-Q
26 05-15-2018 03-31-2018 10-Q
27 03-29-2018 12-31-2017 10-K
28 11-13-2017 09-30-2017 10-Q
29 08-14-2017 06-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 180-life-sciences-reports-positive-topline-results-of-a-clinical-pharmacology-study-testing-a-new-solid-formulation-of-cbd-with-enhanced-oral-uptake-twelve-volunteers-received-all-three-formulations-in-a-crossover-randomized-trial

180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), today announced topline results f...

 180-life-sciences-granted-an-additional-extension-by-nasdaq-hearing-panel-to-regain-compliance-with-continued-listing-requirements

180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), today announced that it received ...

 180-life-sciences-granted-extension-by-nasdaq-hearing-panel-to-regain-compliance-with-continued-listing-requirements

- SEC Filing

 180-life-sciences-says-james-n-woody-resigned-as-ceo-and-as-board-member-on-may-7-2024

On May 7, 2024, Dr. Jonathan Rothbard resigned as Chief Scientific Officer of the Company

 180-life-sciences-regains-full-compliance-with-nasdaq-minimum-bid-price-requirement

180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), today announced that the Company ...

 180-life-sciences-to-conduct-reverse-stock-split-of-its-outstanding-shares-of-common-stock-at-1-for-19-ratio

The Reverse Stock Split is expected to become effective on February 28, 2024 at 12:01 p.m. Eastern Time, with shares expected t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION